Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T18636 |
PROTAC ERα Degrader-1
|
Others; PROTACs | Others; PROTAC |
PROTAC ERα Degrader-1 is a chemical compound. It consists of a ubiquitin E3 ligase binding group, a linker, and a protein binding group. This compound serves as a degrader of estrogen receptor-alpha (ERα). | |||
T74375 | PROTAC ERα Y537S degrader-1 | ||
PROTACERαY537S degrader-1 包含泛素 E3 连接酶结合基团,linker 和靶蛋白结合基团。PROTACERαY537S degrader-1 是雌激素受体-α (ERα) Y537S 的降解剂。 | |||
T18605 |
PROTAC ERα Degrader-2
|
Others; PROTACs | Others; PROTAC |
PROTAC ERα Degrader-2 comprises a cIAP1 ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs)[1]. | |||
T18607 |
PROTAC ER Degrader-3
|
Others | Others |
PROTAC ER Degrader-3, an intermediate for the synthesis of PAC, specifically compound LP2. PAC serves as the linker for ADCs and PROTACs that are conjugated to an antibody. Notably, when PAC is conjugated to an antibody, it exhibits enhanced degradation of estrogen receptor-alpha (ERα) compared to PROTAC alone [1]. | |||
T18606 |
PROTAC ER Degrader-2
|
Others | Others |
PROTAC ER Degrader-2 serves as a synthesis intermediate for the production of PAC, a compound that incorporates the ADCs linker and PROTACs, which are subsequently conjugated to an antibody. PAC, exhibits a greater capability to degrade estrogen receptor-alpha (ERα) compared to PROTAC (without the presence of an antibody)[1]. | |||
T78824 |
ERD-3111
|
Estrogen Receptor/ERR | Endocrinology/Hormones |
ERD-3111 (Compound 44) 是一种口服活性PROTAC ERα降解剂,DC50为0.5 nM。该化合物有效抑制含野生型ER的MCF-7异种移植模型以及两种携带ESR1突变的临床相关小鼠模型中的肿瘤生长,可用于研究ER+乳腺癌。 |